// App-Quantinova.ai

CTIM-32 : IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT

Researchers

Presenter

  • Marta Penas-Prado

Principal Investigators

  • Kathleen Wall

  • Elizabeth Vera

  • Ukeme Ikiddeh-Barnes

  • Katie Blackburn

  • Claudia Chambers

  • Nivi Ratnam

  • Stephen Frederico

  • Alvina Acquaye

  • Kenneth Aldape

  • Nicole Briceno

  • Anna Choi

  • Alexa Christ

  • Varna Jammula

  • Heather Leeper

  • Jason Levine

  • Matthew Lindsley

  • Jennifer Reyes

  • Kayla Roche

  • James Rogers

  • Michael Timmer

  • Lisa Boris

  • Eric Burton

  • Nicole Lollo

  • Marissa Panzer

  • Lily Polskin

  • Valentina Pillai

  • Martha Quezado

  • Brett Theeler

  • Jing Wu

  • Terri Armstrong

  • Mark Gilbert

Medical Centers

  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA

  • NIH, Bethesda, MD, USA

  • National Institutes of Health, Uniformed Services University, Bethesda, MD, USA

  • Laboratory of Pathology, National Institutes of Health, Bethesda, MD, USA

  • National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • Unknown

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT03173950

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved